Table 2.

Odds ratios and 95% confidence intervals for adenoma according to quartile of 25-hydroxyvitamin D level

	Quartile of serum 25(OH) D levels				P for trend
	Quartile1	Quartile2	Quartile3	Quartile4
All patients
Median (ng/mL)	10.33	14.25	17.91	24.21
Case/control	37/28	26/28	28/28	21/28
Model 1	1.00	0.71 (0.35-1.45)	0.73 (0.33-1.61)	0.52 (0.23-1.20)	0.15
Model 2	1.00	0.72 (0.31-1.66)	0.73 (0.29-1.82)	0.49 (0.19-1.27)	0.16
Men
Median (ng/mL)	11.08	14.6	17.65	22.66
Case/control	15/14	13/14	17/15	12/14
Model 1	1.00	0.95 (0.35-2.57)	1.10 (0.29-4.18)	0.80 (0.25-2.60)	0.74
Model 2	1.00	1.31 (0.36-4.82)	1.26 (0.23-6.87)	1.80 (0.40-8.12)	0.46
Women
Median (ng/mL)	9.48	13.53	18.4	25.42
Case/control	16/14	22/14	8/14	9/13
Model 1	1.00	1.31 (0.53-3.24)	0.51 (0.18-1.51)	0.65 (0.20-2.14)	0.16
Model 2	1.00	0.89 (0.26-3.10)	0.54 (0.13-2.16)	0.22 (0.04-1.15)	0.05

Model 1 was adjusted for age (continuous). Model 2 was adjusted for the following covariates; men: age (years, continuous), body mass index (BMI) (kg/m², 18.5- < 23, 23- < 25, > 25), alcohol drinking (nondrinker, past drinker, ≤ 1/mo, 2-4/mo, 2-3/wk, ≥ 4/wk), smoking status (never, 0- < 20, 20- < 30, > 30 pack-years of smoking), and folate intake (mcg/d, continuous); women: age (years, continuous), BMI (kg/m², 18.5- < 23, 23- < 25, > 25), alcohol drinking (nondrinker, ever drinker), smoking status (never, ever smoker), folate intake (mcg/d, continuous), and menopausal status and hormone replacement use (premenopausal, postmenopausal without hormone replacement therapy, postmenopausal with hormone replacement therapy, postmenopausal with nonresponse about hormone replacement therapy use).